Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.

PURPOSE Undetected cancer in repeat transrectal ultrasound guided prostate biopsies in patients with increased prostate specific antigen greater than 4 ng/ml is a considerable concern. We investigated the tumor detection rate of tumor suspicious regions on multimodal 3 Tesla magnetic resonance imaging and subsequent magnetic resonance imaging guided biopsy in 68 men with repeat negative transrectal ultrasound guided prostate biopsies. We compared results to those in a matched transrectal ultrasound guided prostate biopsy population. Also, we determined the clinical significance of detected tumors. MATERIALS AND METHODS A total of 71 consecutive patients with prostate specific antigen greater than 4 ng/ml and 2 or greater negative transrectal ultrasound guided prostate biopsy sessions underwent multimodal 3 Tesla magnetic resonance imaging. In 68 patients this was followed by magnetic resonance imaging guided biopsy directed toward tumor suspicious regions. A matched multisession transrectal ultrasound guided prostate biopsy population from our institutional database was used for comparison. The clinical significance of detected tumors was established using accepted criteria, including prostate specific antigen, Gleason grade, stage and tumor volume. RESULTS The tumor detection rate of multimodal 3 Tesla magnetic resonance imaging guided biopsy was 59% (40 of 68 cases) using a median of 4 cores. The tumor detection rate was significantly higher than that of transrectal ultrasound guided prostate biopsy in all patient subgroups (p <0.01) except in those with prostate specific antigen greater than 20 ng/ml, prostate volume greater than 65 cc and prostate specific antigen density greater than 0.5 ng/ml/cc, in which similar rates were achieved. Of the 40 patients with identified tumors 37 (93%) were considered highly likely to harbor clinically significant disease. CONCLUSIONS Multimodal magnetic resonance imaging is an effective technique to localize prostate cancer. Magnetic resonance imaging guided biopsy of tumor suspicious regions is an accurate method to detect clinically significant prostate cancer in men with repeat negative biopsies and increased prostate specific antigen.

[1]  Hartwig Huland,et al.  Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. , 2003, The Journal of urology.

[2]  H. Klocker,et al.  Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. , 2010, European urology.

[3]  T. Kamoto,et al.  Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort. , 2010, Japanese journal of clinical oncology.

[4]  Koji Okihara,et al.  Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. , 2002, Urology.

[5]  H. Ozen,et al.  Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. , 2005, The Journal of urology.

[6]  John A. Taylor,et al.  Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. , 2002, Urology.

[7]  P. Troncoso,et al.  A nomogram for predicting low‐volume/low‐grade prostate cancer , 2007, Cancer.

[8]  E J Halpern,et al.  Using gray-scale and color and power Doppler sonography to detect prostatic cancer. , 2000, AJR. American journal of roentgenology.

[9]  A. Zisman,et al.  Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. , 2008, Urology.

[10]  B. Kiefer,et al.  Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device , 2006, European Radiology.

[11]  Olivier Cussenot,et al.  Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. , 2011, European urology.

[12]  F. Aragona,et al.  Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. , 2007, Urology.

[13]  Heinz-Peter Schlemmer,et al.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. , 2006, European urology.

[14]  H. Cammann,et al.  A [‐2]proPSA‐based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases , 2009, The Prostate.

[15]  A. Haese*,et al.  High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. , 2006, European urology.

[16]  P. Walsh.  The definition and preoperative prediction of clinically insignificant prostate cancer. , 1996, The Journal of urology.

[17]  J. Patard,et al.  Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. , 2009, European urology.

[18]  G. Bartsch,et al.  Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. , 2005, The Journal of urology.

[19]  G Bartsch,et al.  Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. , 2007, The Journal of urology.

[20]  Thomas Hambrock,et al.  Thirty-Two-Channel Coil 3T Magnetic Resonance-Guided Biopsies of Prostate Tumor Suspicious Regions Identified on Multimodality 3T Magnetic Resonance Imaging: Technique and Feasibility , 2008, Investigative radiology.

[21]  D. Bostwick,et al.  The definition and preoperative prediction of clinically insignificant prostate cancer. , 1996, JAMA.

[22]  C. Gratzke,et al.  Editorial comment on: Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. , 2009, European urology.

[23]  Mesut Remzi,et al.  Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European prostate cancer detection study , 2001, The Prostate.

[24]  P. Javlé,et al.  Importance of peripheral biopsies in maximising the detection of early prostate cancer in repeat 12‐core biopsy protocols , 2006, BJU international.

[25]  Hideaki Miyake,et al.  A comparison of the biological features between prostate cancers arising in the transition and peripheral zones , 2005, BJU international.

[26]  Sudhir Srivastava,et al.  A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[27]  D. Beyersdorff,et al.  MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. , 2005, Radiology.

[28]  John Kurhanewicz,et al.  Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. , 2009, European urology.

[29]  Thomas Hambrock,et al.  Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. , 2007, Radiology.

[30]  Clare Allen,et al.  Is it time to consider a role for MRI before prostate biopsy? , 2009, Nature Reviews Clinical Oncology.

[31]  S. Fukuhara,et al.  Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. , 2008, Japanese journal of clinical oncology.

[32]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[33]  M. Graefen,et al.  Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. , 2003, European urology.

[34]  P. Troncoso,et al.  The relationship between serum prostate specific antigen level and tumor volume persists in the current era. , 2007, The Journal of urology.

[35]  D. Dearnaley,et al.  A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. , 2009, European urology.

[36]  P. Choyke,et al.  Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies , 2008, Computer aided surgery : official journal of the International Society for Computer Aided Surgery.

[37]  K. Harada,et al.  Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ‐confined disease , 2005, International journal of urology : official journal of the Japanese Urological Association.

[38]  H. Huisman,et al.  Accurate estimation of pharmacokinetic contrast‐enhanced dynamic MRI parameters of the prostate , 2001, Journal of magnetic resonance imaging : JMRI.

[39]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[40]  Alan W Partin,et al.  Characteristics of insignificant clinical T1c prostate tumors , 2004, Cancer.

[41]  Hardev Pandha,et al.  Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer , 2011, Clinical Cancer Research.

[42]  William J Catalona,et al.  Serial biopsy results in prostate cancer screening study. , 2002, The Journal of urology.

[43]  Evis Sala,et al.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.